Targeting Axl with an high-affinity inhibitory aptamer. - Wikidata - awgldk - TriplyDB

Targeting Axl with an high-affinity inhibitory aptamer.

Targeting Axl with an high-affinity inhibitory aptamer.

http://www.wikidata.org/entity/Q36460465

about

Aptamers: A promising chemical antibody for cancer therapy Generation of Aptamers with an Expanded Chemical Repertoire AXL kinase as a novel target for cancer therapy Nanoparticle ligand presentation for targeting solid tumors Targeting the TAM Receptors in Leukemia Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells Targeting Insulin Receptor with a Novel Internalizing Aptamer Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.How to train your dragon: targeted delivery of microRNA to cancer cells in vivo.Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers Effect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer.An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.Axl as a mediator of cellular growth and survival Identification of epithelial ovarian tumor-specific aptamers.Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.Imaging Axl expression in pancreatic and prostate cancer xenografts.The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer.The application of aptamers in cancer research: an up-to-date review.Application of aptamers for targeted therapeutics.The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.Current progress on aptamer-targeted oligonucleotide therapeutics.Oligonucleotide aptamers: new tools for targeted cancer therapy.Aptamers as drug delivery vehicles.Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells.Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX.Trends in aptamer selection methods and applications.Aptamers Selected to Postoperative Lung Adenocarcinoma Detect Circulating Tumor Cells in Human Blood.Nucleic acid aptamers in cancer research, diagnosis and therapy.Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.Aptamers as Therapeutics.AXL receptor tyrosine kinase as a therapeutic target in NSCLC.MicroRNAs in the Pathobiology and Therapy of Atherosclerosis.Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.Axl Receptor Axis: A New Therapeutic Target in Lung Cancer.Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.Current Advances in Aptamers for Cancer Diagnosis and Therapy.

P2860

Q26766832-6A602BE1-C330-41A1-AEDB-48A5F6469887 Q26782794-136D1C2C-FFCE-49A6-A9BA-B407FED7BF06 Q26863442-552367CA-EB57-47F1-BD33-ECBCA893706B Q27009522-1FFCFE70-3764-4A7B-B035-A20C0104C64C Q28078654-DC1E9172-F34A-46E0-B88B-9CE730FA2B5A Q28080168-5FC0CB95-B773-43DC-B521-F6E20F9E7517 Q28551045-54041836-55E7-4C19-A89F-CE35DF172EDA Q28822291-524EE1A7-AE98-4EE5-BBBA-DBB2B65C7CE5 Q30250273-6FAA21C4-FC13-43AE-8378-76936FD6C8FD Q33724277-566036DC-B4B1-4CF4-9457-C880FF540C49 Q33724285-1E5392D2-ACC6-4A76-BC1B-69E3895E9554 Q33832781-73D68DAD-E650-4EED-829F-444677C7ED37 Q33847457-EC13CDEA-F733-466B-B674-41873FAE4BEA Q34439798-CDA6C577-82EF-49D1-B759-C1B5AE1B2AFA Q34619118-095EA87B-5F9F-47FE-B8E8-85D9EB199936 Q35635298-027D7F5A-2261-4F1E-B56E-4959883CA3C4 Q37238771-BFE5E4D1-BCE5-4498-9353-39F4E076BFBE Q37571724-B8699EFB-BF81-4B46-989C-E2CD38DCB6D0 Q37627397-FB7730A6-7E3C-40D4-B48C-AE1A6873A660 Q37696048-DA062CD9-F750-43FB-B2BC-6D2F7966D402 Q38087391-9A68F98C-3989-4221-B56E-BC8ACFA5A8EC Q38096870-AE95F6A7-492C-4D69-B57D-BBD520FCA4D0 Q38104686-88C07289-DCBB-4C0A-B729-A165846398F4 Q38168595-1445D20D-EB28-4F92-A42B-0B3D39C577C8 Q38237132-D0738DF8-7281-47CC-B317-61C07834E4BC Q38240594-6BAA9E85-092E-4556-98B2-22B318739E9A Q38270186-55746162-662D-4882-98A2-99BB26C7DFF5 Q38287579-D39B7BE1-7AF8-4853-93C9-5A837E4D32C3 Q38298067-BB9B74FC-8F54-4014-9563-C1C883FE10CF Q38298414-BC3F8BB2-6551-421F-AE16-C5F86B9FF5E5 Q38308357-CB5A6D87-B973-4566-9ABF-B6BA111AA9B9 Q38491805-2E4924D0-9204-44B5-A1B5-09D94B0E3D3C Q38940140-6354700C-9DDF-4CF8-983E-3B1DE72C2F57 Q39070782-EB00C5FC-4E47-4054-A762-157007768CBF Q39139917-02ADCEB7-868B-4645-8CDF-53A95C66A353 Q39148384-19217D54-FE1F-4858-88F9-25AC8ECCE6F3 Q39157476-EB723395-B4AC-45EF-A321-D80B9A19511F Q41953242-9B59AE0F-1FCA-4A12-AE66-60AD64F93EA3 Q47141265-C5DD8A3F-99ED-40FA-9B24-32EFA91748CB Q47561686-676E5190-583D-4D44-93BC-C6C385F8B94F

P2860

Targeting Axl with an high-affinity inhibitory aptamer.

http://www.wikidata.org/entity/Q36460465

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Targeting Axl with an high-affinity inhibitory aptamer.

@ast

Targeting Axl with an high-affinity inhibitory aptamer.

@en

type

label

Targeting Axl with an high-affinity inhibitory aptamer.

@ast

Targeting Axl with an high-affinity inhibitory aptamer.

@en

prefLabel

Targeting Axl with an high-affinity inhibitory aptamer.

@ast

Targeting Axl with an high-affinity inhibitory aptamer.

@en

P1433

Q36460465-0D93B4F5-E17F-43C6-8808-50C1AF7BE141

P1476

Q36460465-F67FDED6-9341-4D29-BB0C-3A9546B36881

P2093

Q36460465-058F4FF3-0DA3-4D0B-A816-A8F4BE018491

Q36460465-29EA0145-2A70-42ED-9075-1556FCAF0243

Q36460465-44F1634A-AFE4-435A-8E98-771369057660

Q36460465-57D55DC8-1B99-4FEB-8D57-E3715ED31FF1

Q36460465-5AA786E7-8658-4352-90F9-AA8661F74BAA

Q36460465-5FC58C08-13CA-49FB-A19E-F090F3F8266F

P2860

Q36460465-082564FB-123E-4BD8-B7BD-45E17A4C9137

Q36460465-0BEA0F05-3620-43D5-BAEC-13E984E8E737

Q36460465-0DEA951E-016C-48DB-BF34-BC3352E6574D

Q36460465-0E2522A1-8CC3-4BFF-AE79-C18F44D515C8

Q36460465-0FF202C0-1237-4749-B7BD-271BCB2F1BB4

Q36460465-1166729E-FD08-4172-8C67-B5B87E51E19E

Q36460465-13A6F4DF-53A8-4B4E-93C8-7752F1AA6F3F

Q36460465-1577391A-CCF5-4416-835B-34CBB6168F0D

Q36460465-1DCF61F6-67D9-4472-BB81-3C13656035B4

Q36460465-24F92DC9-3EFA-4F46-BCE5-BAEFF384AB1A

P304

Q36460465-BDAE8AC9-D93C-4639-B77B-A979317A005B

P31

Q36460465-7E1EF126-A261-4476-8B64-F99C7A8156EF

P356

Q36460465-73AD36E6-7526-4B7B-BB7C-B93E23D88419

P433

Q36460465-375340F9-1B4D-441B-AA25-5EE8709F8F17

P478

Q36460465-D4644739-8BBA-4B4D-9432-E7E41351E710

P50

Q36460465-AB3DFF77-A5DD-4B0D-8F27-DF9081926770

Q36460465-CF461014-2CAA-4F23-9B33-54B9362B2FBB

P577

Q36460465-7376E6CA-A18E-4F1D-9F0F-357EE4B58E3D

P5875

Q36460465-4425958B-0880-4E1A-A4B9-968136A59EF4

P698

Q36460465-F96DFC75-A16B-4C56-9915-B39017AC26E1

P932

Q36460465-2F174B2B-16DE-4921-A278-6D640040D9E4

P356

P1433

Molecular Therapy

P1476

Targeting Axl with an high-affinity inhibitory aptamer

@en

P2093

Andrea Affuso

http://www.w3.org/2001/XMLSchema#string

Anna Rienzo

http://www.w3.org/2001/XMLSchema#string

Loredana Stasio

http://www.w3.org/2001/XMLSchema#string

Luigi Insabato

http://www.w3.org/2001/XMLSchema#string

Simona Camorani

http://www.w3.org/2001/XMLSchema#string

Vittorio de Franciscis

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site

Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6

Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival

Epithelial-mesenchymal transitions in tumour progression

Integrins: bidirectional, allosteric signaling machines

Identification of human brain tumour initiating cells

Identification of a cancer stem cell in human brain tumors

Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl

Both protein S and Gas6 stimulate outer segment phagocytosis by cultured rat retinal pigment epithelial cells

P304

2291-2303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2012.163

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Carla Lucia Esposito

P577

2012-08-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230713800

http://www.w3.org/2001/XMLSchema#string

P698

22910292

http://www.w3.org/2001/XMLSchema#string

P932

3519989

http://www.w3.org/2001/XMLSchema#string